{"id":62757,"date":"2026-03-09T10:02:50","date_gmt":"2026-03-09T09:02:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/"},"modified":"2026-03-09T10:02:50","modified_gmt":"2026-03-09T09:02:50","slug":"naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/","title":{"rendered":"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent"},"content":{"rendered":"
\n

\nCollaboration supports Controlled Human Infection Model (CHIM) studies that help accelerate development of effective and affordable RSV vaccines<\/b><\/p>\n

NANTES, France & GENEVA–(BUSINESS WIRE)–Naobios, a Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and GMP production of clinical batches of virus-based products, and SGS, the world\u2019s leading testing, inspection and certification company, today announce their partnership in the manufacturing of a Respiratory Syncytial Virus (RSV) <\/b>challenge agent for use in Controlled Human Infection Model (CHIM) studies conducted by SGS.<\/p>\n

<\/a>
<\/a><\/p>\n

\nProduced under cGMP conditions, the Human Viral Challenge Agent (HVCA) is derived from a 2015 A-strain isolate that closely mirrors currently circulating RSV strains, with its realistic infection profile allowing researchers to generate robust, decision-enabling data on vaccine efficacy and immune response dynamics.<\/p>\n

\nNaobios has already successfully completed the development, manufacturing and filling of several HVCAs for study use on the global market. HVCAs are used in strictly controlled clinical trials (or CHIM studies) in which healthy volunteers are intentionally given a carefully considered dose of a pathogen inoculated under rigorous ethical, regulatory and biosafety oversight to evaluate prophylactic vaccines or curative treatments.<\/p>\n

\nThese studies enable early and cost-efficient evaluation of RSV vaccines to prevent infection.<\/p>\n

\nTo generate first\u2011in\u2011human proof-of-concept data, in October 2025 12 healthy participants were inoculated at the SGS Clinical Pharmacology Unit in Antwerp, Belgium, with the RSV A-strain challenge agent. The participants showed a 100% attack rate with mild, self-resolving pathology.<\/p>\n

\n\u201cIn response to the growing use of CHIM studies, we have invested to extend our range of services, enabling us to meet the critical needs of clients worldwide,\u201d said Eric Le Forestier, general manager of Naobios. \u201cThis partnership with SGS demonstrates that Naobios continues to be a key global player and first-choice partner for viral challenge agent manufacturing in accordance with cGMP.\u201d<\/p>\n

\nAbout Naobios<\/b><\/p>\n

\nNaobios is a Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and offering GMP production of clinical batches of BSL2\/BSL3 viral vaccines, oncolytic viruses, viral vectors and human viral challenge agents. Naobios joined the Clean Biologics group in 2019.<\/p>\n

\nHaving built up 20 years\u2019 experience in bioprocess development, Naobios helps its clients to bring their drug candidates to the clinical stage as rapidly as possible \u2013 at the highest level of quality \u2013 whilst building on its technical know-how in scalable and industrial processes.<\/p>\n

\nwww.naobios.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nLorraine Walters
\n
lorraine@ala.associates<\/a><\/p>\n

\nC\u00e9line Gonzalez
\n
celine@ala.associates<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Collaboration supports Controlled Human Infection Model (CHIM) studies that help accelerate development of effective and affordable RSV vaccines NANTES, France & GENEVA–(BUSINESS WIRE)–Naobios, a Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and GMP production of clinical batches of virus-based products, and SGS, the world\u2019s leading testing, inspection and certification company, today announce their … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62757","6":"format-standard","7":"category-industry"},"yoast_head":"\nNaobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Collaboration supports Controlled Human Infection Model (CHIM) studies that help accelerate development of effective and affordable RSV vaccines NANTES, France & GENEVA–(BUSINESS WIRE)–Naobios, a Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and GMP production of clinical batches of virus-based products, and SGS, the world\u2019s leading testing, inspection and certification company, today announce their ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T09:02:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260309874853\/en\/2727822\/22\/Naobios.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent\",\"datePublished\":\"2026-03-09T09:02:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/\"},\"wordCount\":408,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260309874853\\\/en\\\/2727822\\\/22\\\/Naobios.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/\",\"name\":\"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260309874853\\\/en\\\/2727822\\\/22\\\/Naobios.jpg\",\"datePublished\":\"2026-03-09T09:02:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260309874853\\\/en\\\/2727822\\\/22\\\/Naobios.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260309874853\\\/en\\\/2727822\\\/22\\\/Naobios.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/","og_locale":"en_US","og_type":"article","og_title":"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent - Pharma Trend","og_description":"Collaboration supports Controlled Human Infection Model (CHIM) studies that help accelerate development of effective and affordable RSV vaccines NANTES, France & GENEVA–(BUSINESS WIRE)–Naobios, a Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and GMP production of clinical batches of virus-based products, and SGS, the world\u2019s leading testing, inspection and certification company, today announce their ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-09T09:02:50+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260309874853\/en\/2727822\/22\/Naobios.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent","datePublished":"2026-03-09T09:02:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/"},"wordCount":408,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260309874853\/en\/2727822\/22\/Naobios.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/","url":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/","name":"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260309874853\/en\/2727822\/22\/Naobios.jpg","datePublished":"2026-03-09T09:02:50+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260309874853\/en\/2727822\/22\/Naobios.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260309874853\/en\/2727822\/22\/Naobios.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/naobios-and-sgs-partner-to-manufacture-respiratory-syncytial-virus-rsv-challenge-agent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62757"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62757\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}